YaBeSH Engineering and Technology Library

    • Journals
    • PaperQuest
    • YSE Standards
    • YaBeSH
    • Login
    View Item 
    •   YE&T Library
    • ASME
    • Journal of Medical Devices
    • View Item
    •   YE&T Library
    • ASME
    • Journal of Medical Devices
    • View Item
    • All Fields
    • Source Title
    • Year
    • Publisher
    • Title
    • Subject
    • Author
    • DOI
    • ISBN
    Advanced Search
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Archive

    Development and Validation of Endovascular Chemotherapy Filter Device for Removing High Dose Doxorubicin: Preclinical Study

    Source: Journal of Medical Devices:;2014:;volume( 008 ):;issue: 004::page 41008
    Author:
    Patel, Anand S.
    ,
    Saeed, Maythem
    ,
    Yee, Erin J.
    ,
    Yang, Jeffrey
    ,
    Lam, Gregory J.
    ,
    Losey, Aaron D.
    ,
    Lillaney, Prasheel V.
    ,
    Thorne, Bradford
    ,
    Chin, Albert K.
    ,
    Malik, Sheena
    ,
    Wilson, Mark W.
    ,
    Chen, Xi C.
    ,
    Balsara, Nitash P.
    ,
    Hetts, Steven W.
    DOI: 10.1115/1.4027444
    Publisher: The American Society of Mechanical Engineers (ASME)
    Abstract: To develop a novel endovascular chemotherapy filter (CF) able to remove excess drug from the blood during intraarterial chemotherapy delivery (IAC), thus preventing systemic toxicities and thereby enabling higher dose IAC. A flow circuit containing 2.5 mL of ionexchange resin was constructed. Phosphatebuffered saline (PBS) containing 50 mg doxorubicin (Dox) was placed in the flow model with the hypothesis that doxorubicin would bind rapidly to resin. To simulate IAC, 50 mg of doxorubicin was infused over 10 min into the flow model containing resin. Similar testing was repeated with porcine serum. Doxorubicin concentrations were measured over 60 min and compared to controls (without resin). Singlepass experiments were also performed. Based on these experiments, an 18F CF was constructed with resin in its tip. In a pilot porcine study, the device was deployed under fluoroscopy. A control hepatic doxorubicin IAC model (no CF placed) was developed in another animal. A second CF device was created with a resin membrane and tested in the infrarenal inferior vena cava (IVC) of a swine. In the PBS model, resin bound 76% of doxorubicin in 10 min, and 92% in 30 min (P < 0.001). During IAC simulation, 64% of doxorubicin bound in 10 min and 96% in 60 min (P < 0.001). On average, 51% of doxorubicin concentration was reduced during each pass in single pass studies. In porcine serum, 52% of doxorubicin bound in 10 min, and 80% in 30 min (P < 0.05). CF device placement and administration of IAC were successful in three animals. No clot was present on the resin within the CF following the in vivo study. The infrarenal IVC swine study demonstrated promising results with up to 85% reduction in peak concentration by the CF device. An endovascular CF device was developed and shown feasible in vitro. An in vivo model was established with promising results supporting highcapacity rapid doxorubicin filtration from the blood that can be further evaluated in future studies.
    • Download: (1.253Mb)
    • Show Full MetaData Hide Full MetaData
    • Get RIS
    • Item Order
    • Go To Publisher
    • Price: 5000 Rial
    • Statistics

      Development and Validation of Endovascular Chemotherapy Filter Device for Removing High Dose Doxorubicin: Preclinical Study

    URI
    http://yetl.yabesh.ir/yetl1/handle/yetl/155964
    Collections
    • Journal of Medical Devices

    Show full item record

    contributor authorPatel, Anand S.
    contributor authorSaeed, Maythem
    contributor authorYee, Erin J.
    contributor authorYang, Jeffrey
    contributor authorLam, Gregory J.
    contributor authorLosey, Aaron D.
    contributor authorLillaney, Prasheel V.
    contributor authorThorne, Bradford
    contributor authorChin, Albert K.
    contributor authorMalik, Sheena
    contributor authorWilson, Mark W.
    contributor authorChen, Xi C.
    contributor authorBalsara, Nitash P.
    contributor authorHetts, Steven W.
    date accessioned2017-05-09T01:11:22Z
    date available2017-05-09T01:11:22Z
    date issued2014
    identifier issn1932-6181
    identifier othermed_008_04_041008.pdf
    identifier urihttp://yetl.yabesh.ir/yetl/handle/yetl/155964
    description abstractTo develop a novel endovascular chemotherapy filter (CF) able to remove excess drug from the blood during intraarterial chemotherapy delivery (IAC), thus preventing systemic toxicities and thereby enabling higher dose IAC. A flow circuit containing 2.5 mL of ionexchange resin was constructed. Phosphatebuffered saline (PBS) containing 50 mg doxorubicin (Dox) was placed in the flow model with the hypothesis that doxorubicin would bind rapidly to resin. To simulate IAC, 50 mg of doxorubicin was infused over 10 min into the flow model containing resin. Similar testing was repeated with porcine serum. Doxorubicin concentrations were measured over 60 min and compared to controls (without resin). Singlepass experiments were also performed. Based on these experiments, an 18F CF was constructed with resin in its tip. In a pilot porcine study, the device was deployed under fluoroscopy. A control hepatic doxorubicin IAC model (no CF placed) was developed in another animal. A second CF device was created with a resin membrane and tested in the infrarenal inferior vena cava (IVC) of a swine. In the PBS model, resin bound 76% of doxorubicin in 10 min, and 92% in 30 min (P < 0.001). During IAC simulation, 64% of doxorubicin bound in 10 min and 96% in 60 min (P < 0.001). On average, 51% of doxorubicin concentration was reduced during each pass in single pass studies. In porcine serum, 52% of doxorubicin bound in 10 min, and 80% in 30 min (P < 0.05). CF device placement and administration of IAC were successful in three animals. No clot was present on the resin within the CF following the in vivo study. The infrarenal IVC swine study demonstrated promising results with up to 85% reduction in peak concentration by the CF device. An endovascular CF device was developed and shown feasible in vitro. An in vivo model was established with promising results supporting highcapacity rapid doxorubicin filtration from the blood that can be further evaluated in future studies.
    publisherThe American Society of Mechanical Engineers (ASME)
    titleDevelopment and Validation of Endovascular Chemotherapy Filter Device for Removing High Dose Doxorubicin: Preclinical Study
    typeJournal Paper
    journal volume8
    journal issue4
    journal titleJournal of Medical Devices
    identifier doi10.1115/1.4027444
    journal fristpage41008
    journal lastpage41008
    identifier eissn1932-619X
    treeJournal of Medical Devices:;2014:;volume( 008 ):;issue: 004
    contenttypeFulltext
    DSpace software copyright © 2002-2015  DuraSpace
    نرم افزار کتابخانه دیجیتال "دی اسپیس" فارسی شده توسط یابش برای کتابخانه های ایرانی | تماس با یابش
    yabeshDSpacePersian
     
    DSpace software copyright © 2002-2015  DuraSpace
    نرم افزار کتابخانه دیجیتال "دی اسپیس" فارسی شده توسط یابش برای کتابخانه های ایرانی | تماس با یابش
    yabeshDSpacePersian